Forest Laboratories Inc

Forest Laboratories — Merger or Acquisition (April 2014)

16 slides from Forest Laboratories's merger presentation, Apr 29, 2014

  1. Slide 1: Forest to Acquire Furiex for $1.1 Billion

    Exhibit 99.3 Forest to Acquire Furiex for $1.1 Billion 4/28/2014 © 2013 Forest Laboratories Inc.

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including that the transactions may not be timely completed, if at all, that prior to completion

  3. Slide 3: Safe Harbor - continued

    Safe Harbor - continued Neither Forest nor Furiex assumes any obligation to update forward-looking statements contained in this release to reflect new information or future events or developments. Each of Forest and Furiex intends such forward-looking statements to be covered by the Safe Harbor prov

  4. Slide 4: Additional Information and Where to Find It

    Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale

  5. Slide 5: Registration statement not yet effective; proxy and prospectus notice

    The registration statement is not yet effective. The definitive Forest/Actavis Proxy and Prospectus will be delivered to security holders of Actavis and Forest. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE FURIEX PROXY, THE FOREST/ACTAVIS PROXY AND PROSPECTUS AND OTHER RELEVANT DOCUMENTS FIL

  6. Slide 6: Participants in the Solicitation

    Participants in the Solicitation Forest, Furiex and their directors and certain of their executive officers may be considered participants in the solicitation of proxies from the security holders of Furiex in connection with the proposed transaction between Forest and Furiex. Information about those

  7. Slide 7: Actavis and Forest participants in the solicitation

    Actavis, Forest, their respective directors and certain of their executive officers and employees may be considered participants in the solicitation of proxies in connection with the proposed transaction between Actavis and Forest. Information regarding the persons who may, under the rules of the SE

  8. Slide 8: Furiex Acquisition Rationale

    Furiex Acquisition Rationale • Builds a leading GI company within Forest – Natural extension following Aptalis acquisition in January – Highly complementary to our anchor GI product Linzess • Brings a near-term filing opportunity into Forest's R&D • Expands Forest product offering geographically • G

  9. Slide 9: Forest Goal is to Build an Exceptional Company

    Forest Goal is to Build an Exceptional Company EXECUTION BUSINESS Marketed Drugs development commercial ENGINE AN EXCEPTIONAL COMPANY DRUG NDA development © 2013 Forest Laboratories Inc. 4/28/2014 | 9

  10. Slide 10: Eluxadoline for IBS-D

    Eluxadoline for IBS-D Eluxadoline is a novel mixed mu(µ) opioid receptor agonist/delta( ) opioid receptor antagonist in development for IBS-D – Positive topline Phase 3 data released Feb 2014 – On track to be filed by end of Q3 2014 Mechanism potentially addresses both diarrhea and abdominal pain wi

  11. Slide 11: Eluxadoline Phase 3 Study Design

    Eluxadoline Phase 3 Study Design Two simultaneous studies, one with 52-week and one with 30-week treatment periods, with study centers in the U.S., Canada and U.K. Primary endpoints: composite response at 12 weeks (FDA guidance) and 26 weeks (EMA guidance), as defined¹: – Daily pain score improved b

  12. Slide 12: Significant Efficacy in Two Phase 3 Studies – FDA

    Significant Efficacy in Two Phase 3 Studies – FDA Statistically significant improvements in responder rates through 12 weeks (FDA endpoint) across both Study 3001 and Study 3002 – Rapid onset of action, efficacy both in males and females p < 0.001 p < 0.001 p = 0.004 p = 0.014 28.9% 29.6% 23.9% 25.1

  13. Slide 13: Significant Efficacy in Two Phase 3 Studies – EMA

    Significant Efficacy in Two Phase 3 Studies – EMA Statistically significant improvements in responder rates through 26 weeks (EMA endpoint) across both Study 3001 and Study 3002 – Rapid onset of action with sustained efficacy through 6 months p < 0.001 p = 0.001 p < 0.001 p = 0.11 32.7% 29.3% 30.4%

  14. Slide 14: Pooled Phase 3 Pain Responder Analysis – FDA

    Pooled Phase 3 Pain Responder Analysis – FDA Statistically significant improvements vs. placebo in pre-specified pooled Phase 3 ITT analysis of pain responder rates at 12 weeks¹ – Analysis conducted per FDA request and is consistent with 2012 FDA guidance p = 0.003 p = 0.078 p = 0.011 p = 0.047 1. T

  15. Slide 15: Furiex Transaction Overview

    Furiex Transaction Overview • Acquisition of all outstanding shares of Furiex for ~$1.1 B $95 per share • Transaction also includes Contingent Value Right (CVR) of up to $30 per Furiex share (~$360 million in aggregate) $10 per share if eluxadoline is designated schedule IV drug $20 per share if elu

  16. Slide 16: Commercial Perspective

    Commercial Perspective • Overall GI market valued at $38 billion • IBS-d Affects ~ 28 million in US and Europe • High degree of Physician overlap in IBS-d and IBS-C • New combined GI sales force in place • No significant increase in field promotions required © 2013 Forest Laboratories Inc. 4/28/2014

Forest Laboratories — Merger or Acquisition (April 2014) on 6ix